06:09:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-03-12 Årsstämma 2025
2025-02-05 Bokslutskommuniké 2024
2024-10-22 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-04-23 Kvartalsrapport 2024-Q1
2024-03-13 Ordinarie utdelning EMBLA 0.00 DKK
2024-03-13 Årsstämma 2024
2024-03-12 Årsstämma 2024
2024-01-30 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-25 Kvartalsrapport 2023-Q2
2023-04-25 Kvartalsrapport 2023-Q1
2023-03-13 Ordinarie utdelning EMBLA 0.00 DKK
2023-03-10 Årsstämma 2023
2023-01-31 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-03-09 Ordinarie utdelning EMBLA 0.00 DKK
2022-03-08 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-09 Ordinarie utdelning EMBLA 0.00 DKK
2021-03-08 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-07-23 Kvartalsrapport 2020-Q2
2020-04-30 Kvartalsrapport 2020-Q1
2020-03-13 Ordinarie utdelning EMBLA 0.15 DKK
2020-03-12 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-30 Kvartalsrapport 2019-Q1
2019-03-08 Ordinarie utdelning EMBLA 0.14 DKK
2019-03-07 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-25 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-09 Ordinarie utdelning EMBLA 0.13 DKK
2018-03-08 Årsstämma 2018
2018-02-05 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-07-25 Kvartalsrapport 2017-Q2
2017-04-27 Kvartalsrapport 2017-Q1
2017-03-10 Ordinarie utdelning EMBLA 0.12 DKK
2016-03-11 Ordinarie utdelning EMBLA 0.12 DKK
2016-03-10 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-07-23 Kvartalsrapport 2015-Q2
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-12 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Analytiker möte 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-07-25 Analytiker möte 2014
2014-07-24 Kvartalsrapport 2014-Q2
2014-04-30 Analytiker möte 2014
2014-04-29 Kvartalsrapport 2014-Q1
2014-03-14 Årsstämma 2014
2014-02-05 Bokslutskommuniké 2013
2013-10-24 Analytiker möte 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-07-24 Kvartalsrapport 2013-Q2
2013-04-24 Kvartalsrapport 2013-Q1
2013-03-15 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-11-28 Kapitalmarknadsdag 2012
2012-11-27 Kapitalmarknadsdag 2012
2012-10-24 Analytiker möte 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-07-25 Kvartalsrapport 2012-Q2
2012-04-24 Kvartalsrapport 2012-Q1
2012-03-16 Årsstämma 2012
2012-02-08 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-07-28 Kvartalsrapport 2011-Q2
2011-03-04 Årsstämma 2011

Beskrivning

LandIsland
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Össur hf. är ett isländskt bolag verksamma inom hälsa - och sjukvård. Idag innehas affärsinriktning mot utvecklandet av benproteser, artros samt relaterad skadehantering. Produkterna är anpassade för olika åldrar och förutsättningar beroende på patientens svårighetsgrad. Verksamheten är etablerad globalt med störst marknad inom Europa följt av Nordamerika. Huvudkontoret ligger i Reykjavik.
2019-09-09 18:02:00

Announcement from Össur hf. No. 53/2019
Reykjavík, 9 September 2019

Össur hf. has decided to initiate a new share buyback program (the "Program") tomorrow, 10 September 2019, which will replace the share buyback program that was completed today, 9 September 2019. The Program will be carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052. The purpose of the Program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The Company may purchase up to 5,000,000 shares under the Program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million. The daily purchase shall not exceed 25% of the average volume in the 20 trading days before the purchase on the regulated market where the transaction is carried out. The purchase price shall not be higher than the price of the last independent trade or the highest current independent bid, whichever is higher, on the regulated market where the transaction is carried out. The Program will be managed by Nordea, which shall make its trading decisions independently and without influence by the Company with regards to the timing of the purchases. The Company's purchases under the Program shall be disclosed in accordance with laws and regulations. The Program will end no later than 31 December 2019, but the Company is entitled to discontinue the Program at any time.

The Company also reserves the right to buy back shares in block trades outside the Program with the aim to maintain net interest-bearing debt at 1.0x - 2.0x to EBITDA (excluding the impact of IFRS16 Leasing). Such transactions will only be made outside "black-out periods", i.e. not within 30 days prior to publication of the Company's quarterly financial results, and when no insider information is available. Such transactions will be announced immediately after they have been carried out.

According to an authorization granted by the Annual General Meeting in March 2015, the Company is allowed to purchase own shares of up to 10% of the Company's share capital as it stands each time. The authorization states that the purchase price shall not be higher than the price of the last independent trade or the highest current independent bid, whichever is higher, on the regulated market where the transaction is carried out. The authorization is valid until 12 March 2020.

                                                                                                                

Contact persons:

Jón Sigurðsson, President & CEO                                                   Tel: +354 515 1300

Sveinn Sölvason, CFO                                                                 Tel: +354 515 1300

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings

About Össur Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Forward-Looking Statement This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.